Payment overview · 2025
General Payments
$595.05
9 reported records · 9 companies
Healthcare provider profile · identity verified
Craig B Miller, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PLYMOUTH, IN · NPI 1376571265
Verified facts
What the public records show
CMS Open Payments records show Craig B Miller, M.D. received $595.05 in general payments during 2025 across 9 reported records.
Organogenesis Inc. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $150.00 | 25.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$140.22 | 23.6% | 1 | 2025 |
| Reapplix Inc. | Unresolved — no canonical attribution shown | $126.66 | 21.3% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $53.88 | 9.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $34.45 | 5.8% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $30.72 | 5.2% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.59 | 3.5% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $19.71 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.82 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $595.05 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| PLASMABLADE(TM) Normalized: plasmablade tm |
Device | Medtronic, Inc. | $140.22 | 1 | 2025 |
Source payment records
|
|||||
| 3C Patch Kit - Box Normalized: 3c patch kit box |
Device | Reapplix Inc. | $126.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $53.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $53.88 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $34.45 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. DERMATAC Normalized: v a c dermatac |
Device | Solventum Corporation | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 663 | 227 |
| Levothyroxine Sodium | Levothyroxine Sodium | 546 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 166 |
| Lisinopril | Lisinopril | 385 | 123 |
| Alendronate Sodium | Alendronate Sodium | 257 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 89 |
| Losartan Potassium | Losartan Potassium | 232 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 76 |
| Omeprazole | Omeprazole | 197 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 65 |
| Sertraline Hcl | Sertraline Hcl | 171 | 64 |
| Gabapentin | Gabapentin | 161 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 60 |
| Furosemide | Furosemide | 158 | 57 |
| Metformin Hcl | Metformin Hcl | 147 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 50 |
| Metformin Hcl Er | Metformin Hcl | 128 | 46 |
| Simvastatin | Simvastatin | 118 | 43 |
| Meloxicam | Meloxicam | 116 | 46 |
| Famotidine | Famotidine | 115 | 41 |
| Mounjaro | Tirzepatide | 111 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 34 |
| Glipizide Er | Glipizide | 92 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Prednisone | Prednisone | 85 | 63 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 63 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 28 |
| Allopurinol | Allopurinol | 73 | 22 |
| Potassium Chloride | Potassium Chloride | 73 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 24 |
| Synthroid | Levothyroxine Sodium | 60 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 19 |
| Ozempic | Semaglutide | 56 | 15 |
| Warfarin Sodium | Warfarin Sodium | 54 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 17 |
| Trulicity | Dulaglutide | 51 | 11 |
| Trazodone Hcl | Trazodone Hcl | 50 | 19 |
| Carvedilol | Carvedilol | 49 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 11 |
| Jardiance | Empagliflozin | 48 | 13 |
| Cephalexin | Cephalexin | 47 | 39 |
| Donepezil Hcl | Donepezil Hcl | 47 | 22 |
| Eliquis | Apixaban | 46 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 17 |
| Spironolactone | Spironolactone | 42 | 16 |
| Clotrimazole | Clotrimazole | 40 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 13 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 30 |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | 12 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Colchicine | Colchicine | 32 | 12 |
| Glimepiride | Glimepiride | 32 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Atenolol | Atenolol | 31 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Indapamide | Indapamide | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Estradiol | Estradiol | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $595.05 · 9 records | Organogenesis Inc. | 3C Patch Kit - Box, ACTIV.A.C., Flexitouch Plus, GRAFIX PL, Kerecis GraftGuide, Kerecis SurgiClose, Nimbl, Ozempic, PLASMABLADE(TM), PURAPLY WOUND MATRIX, Rybelsus, V.A.C. DERMATAC | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error